GH001 is our innovative drug product for 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) administration via a proprietary inhalation approach. A Phase 1b study with GH001 in patients with Treatment-Resistant Depression is ongoing. See ghres.com to learn more.

GH Research Ltd. Announces Completion of Phase 1 Clinical Study with GH001 (5-Methoxy-N,N-Dimethyltryptamine) in Healthy Volunteers and Updates on Further Progress ghres.com/investors prnewswire.co.uk/news-releases/…

GH Research Announces Closing of $125 Million Oversubscribed Series B Financing #5meodmt #mentalhealth prnewswire.com/news-releases/…

GH Research Announces Successful Outcome of the Phase 2 part of its Phase 1/2 Clinical Trial of GH001 in Treatment-Resistant Depression globenewswire.com/news-release/2…

GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates globenewswire.com/news-release/2…

GH Research presented further results from a double-blind, placebo-controlled Phase 2b trial in TRD and a POC trial in PPD this week at the American Society of Clinical Psychopharmacology 2025 Annual Meeting – see our scientific publications here: ghres.com/scientific-pub…

GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule investor.ghres.com/news-releases/…